MOTS-c vs SS-31: Which Mitochondrial Peptide Has Better Evidence?
Here is how these two compounds compare — based on published research, not marketing claims.
MOTS-c
194
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
SS-31 (Elamipretide)
481
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
Both MOTS-c and SS-31 (elamipretide) target mitochondria — the energy factories in every cell. But they approach mitochondrial health from different directions. MOTS-c is encoded by mitochondrial DNA itself and acts as a metabolic regulator. SS-31 targets the inner mitochondrial membrane to protect the machinery of energy production. Both have human data. SS-31 is further along in clinical development.
Key Differences
| Attribute | MOTS-c | SS-31 (Elamipretide) |
|---|---|---|
| Evidence Level | Human Trials | Human Trials |
| Category | Mitochondrial-Derived Peptide | Mitochondrial-Targeted Peptide |
| Human Data | Five human studies published. Metabolic effects observed. PSI rates L3. | Multiple Phase II and Phase III trials for Barth syndrome, heart failure, and mitochondrial myopathy. PSI rates L3. |
| Safety Profile | Limited but favorable. Endogenous peptide. No serious adverse events in published human studies. | Clinical trial safety data available. Side effects include injection site reactions. Generally well-tolerated in trials. |
| Key Limitations | Human data is early-stage. Most evidence is animal and mechanistic. | Not yet FDA-approved. Some trials did not meet primary endpoints. Specific indication targeting limits generalizability. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
MOTS-c
Encoded in mitochondrial DNA. Activates AMPK, the master metabolic switch. Improves insulin sensitivity, enhances fatty acid oxidation, and functions as an exercise mimetic. Your mitochondria produce it naturally — levels decline with age.
SS-31 (Elamipretide)
Concentrates on the inner mitochondrial membrane where it binds cardiolipin — a lipid essential for electron transport chain function. Stabilizes the energy-producing machinery directly. Think of it as reinforcing the power plant's turbines.
MOTS-c signals. SS-31 protects. MOTS-c activates AMPK and metabolic pathways throughout the body — it is a messenger from the mitochondria telling the rest of the cell to improve energy metabolism. SS-31 goes directly to the mitochondrial membrane and stabilizes the physical structure where energy production happens. One is a hormone-like signal. The other is structural reinforcement.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 675 indexed studies. Here are the key findings.
Both L3. SS-31 has more advanced clinical development — Phase II/III trials for specific mitochondrial diseases. MOTS-c has fewer but broader metabolic studies. SS-31 is closer to potential FDA approval for specific indications.
For specific mitochondrial diseases, SS-31 has more targeted clinical data.
For metabolic optimization and exercise mimetic effects, MOTS-c has more relevant research.
For age-related mitochondrial decline, both have mechanistic rationale but neither has definitive outcome data.
For clinical development maturity, SS-31 is further along with more advanced trials.
Key Limitations
- •No head-to-head comparison.
- •Neither is FDA-approved.
- •SS-31 trials target specific diseases — results may not generalize.
- •MOTS-c human data is early-stage.
- •Both are at the frontier of mitochondrial medicine.
PSI Verdict
SUPPORTED BY EVIDENCE
MOTS-c activates AMPK and improves metabolic function in human studies. SS-31 stabilizes mitochondrial membranes and has demonstrated effects in Phase II/III trials for mitochondrial diseases and heart failure.
NOT YET ESTABLISHED
Neither has achieved FDA approval. Whether broad mitochondrial support translates to measurable health or longevity outcomes in healthy adults is unproven for both compounds.
CONFIDENCE LEVEL
Moderate for both. SS-31 has more clinical infrastructure behind it. MOTS-c has the more compelling systemic metabolic story. If forced to choose one with better clinical validation, SS-31 is ahead. If the interest is metabolic optimization, MOTS-c is more directly relevant.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
MOTS-c
"MOTS-c is the longevity peptide everyone should be taking"Plausible but unproven
"It improves exercise performance and endurance"Supported by published data
"People are using it as a metabolic reset"Anecdotal only
SS-31 (Elamipretide)
"SS-31 is the most advanced mitochondrial peptide"Supported by evidence
"SS-31 reverses mitochondrial aging"Plausible but unproven in humans
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
MOTS-c
Limited but favorable. Endogenous peptide. No serious adverse events in published human studies.
SS-31 (Elamipretide)
Clinical trial safety data available. Side effects include injection site reactions. Generally well-tolerated in trials.
SS-31 has more formal safety data from clinical trials. MOTS-c is endogenous (your body makes it), which is theoretically favorable, but clinical safety data is more limited.
WHAT THE RESEARCH SUGGESTS
SS-31 is further in clinical development with more advanced trials. MOTS-c has broader metabolic research and the unique advantage of being an endogenous signaling molecule. Both represent the cutting edge of mitochondrial medicine.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.